Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Published:2020-11-16 Issue:12 Volume:130 Page:6656-6667
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Shah Gunjan L.^ORCID,DeWolf Susan^ORCID,Lee Yeon Joo^ORCID,Tamari Roni,Dahi Parastoo B.^ORCID,Lavery Jessica A.^ORCID,Ruiz Josel,Devlin Sean M.,Cho Christina,Peled Jonathan U.^ORCID,Politikos Ioannis,Scordo Michael,Babady N. Esther,Jain Tania^ORCID,Vardhana Santosha^ORCID,Daniyan Anthony,Sauter Craig S.,Barker Juliet N.^ORCID,Giralt Sergio A.^ORCID,Goss Cheryl,Maslak Peter,Hohl Tobias M.^ORCID,Kamboj Mini,Ramanathan Lakshmi,van den Brink Marcel R.M.^ORCID,Papadopoulos Esperanza,Papanicolaou Genovefa,Perales Miguel-Angel^ORCID

Funder

NIH, NCI

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/141777/files/pdf

Reference45 articles.

1. Johns Hopkins Coronavirus Resource Center. COVID-19 United States Cases by County. https://coronavirus.jhu.edu/us-map Accessed Jun 2, 2020

2. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak;Dai;Cancer Discov,2020

3. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent